Tuesday, 16 October 2012

Availability of alemtuzumab

Source MS Trust:

Alemtuzumab is an experimental drug treatment for people with relapsing remitting multiple sclerosis that is currently going through the licensing process with the European Medicines Agency (EMA) and the Federal Drug Administration (FDA) in the US. If approved, it is expected to be marketed under the name Lemtrada. Read more here.